Skip to Content

Talazoparib Dosage

Medically reviewed by Drugs.com. Last updated on Nov 18, 2019.

Applies to the following strengths: 0.25 mg; 1 mg

Usual Adult Dose for Breast Cancer

1 mg orally once a day until disease progression or unacceptable toxicity

Comments:
-Select patients based on the presence of germline BRCA mutations as determined by an FDA-approved test.

Use: For the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer

Renal Dose Adjustments

Mild hepatic impairment (total bilirubin 1 x upper limit of normal [ULN] or less and aspartate aminotransferase [AST] greater than ULN, or total bilirubin greater than 1 to 1.5 x ULN and any AST): No adjustment recommended.
Moderate hepatic impairment (total bilirubin greater than 1.5 to 3 x ULN and any AST or severe hepatic impairment (total bilirubin greater than 3 x ULN and any AST): Data not available

Liver Dose Adjustments

Mild hepatic impairment (total bilirubin 1 x upper limit of normal [ULN] or less and aspartate aminotransferase [AST] greater than ULN, or total bilirubin greater than 1 to 1.5 x ULN and any AST): No adjustment recommended.
Moderate hepatic impairment (total bilirubin greater than 1.5 to 3 x ULN and any AST or severe hepatic impairment (total bilirubin greater than 3 x ULN and any AST): Data not available

Dose Adjustments

DOSE REDUCTIONS FOR ADVERSE REACTIONS:
-Recommended starting dose: 1 mg orally once daily
-First dose reduction: 0.75 mg orally once a day
-Second dose reduction: 0.5 mg orally once a day
-Third dose reduction: 0.25 mg orally once a day

DOSE MODIFICATIONS:
-Hemoglobin less than 8 g/dL: Withhold therapy until levels resolve to 9 g/dL or greater; resume therapy at a reduced dose.
-Platelet count less than 50,000/microliters: Withhold therapy until levels resolve to 75,000 microliters or greater; resume therapy at a reduced dose.
-Neutrophil count less than 1000/microliters: Withhold therapy until levels resolve to 1500 microliters or greater; resume therapy at a reduced dose.
-Nonhematologic Grade 3 or 4: Withhold therapy until levels resolve to Grade 1 or less; Consider resuming therapy at a reduced dose or discontinue therapy.

DOSE MODIFICATIONS FOR USE WITH P-GLYCOPROTEIN (P-GP) INHIBITORS:
-Reduce the dose to 0.75 mg once daily when coadministered with certain P-gp inhibitors.
-When the P-gp inhibitor is discontinued, increase the dose (after 3 to 5 half-lives of the P-gp inhibitor) to the dose used prior to the initiation of the P-gp inhibitor.

Precautions

CONTRAINDICATIONS:
-None

This drug is not recommended for use in children.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:
-This drug may be taken with or without food.
-The capsules should be swallowed whole and not opened or dissolved.
-If the patient vomits or misses a dose, an additional dose should not be taken; take the next prescribed dose at the usual time.

Storage requirements:
-Store at 20C to 25C (68F to 77F); excursions permitted between 15C to 30C (59F to 86F).

Monitoring:
-Monitor complete blood counts monthly.

Patient advice:
-Patients should contact their healthcare provider if they experience weakness, feeling tired, fever, weight loss, frequent infections, bruising, bleeding easily, breathlessness, blood in urine or stool, and/or laboratory findings of low blood cell counts, or a need for blood transfusions.
-Females should inform their healthcare provider if they are pregnant or become pregnant.
-Inform female patients of the risk to a fetus and potential loss of the pregnancy.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Related questions

Hide